Published in Cancer Weekly, July 6th, 2004
A pilot clinical study of epratuzumab, Immunomedics' humanized anti-CD22 monoclonal antibody, in combination with rituximab and CHOP (cyclophosphamide, doxorubicin hydrochloride, Oncovin (vincristine), and prednisone) chemotherapy (ER-CHOP), was studied in previously untreated patients with diffuse large B-cell lymphoma (DLBCL) to assess safety and activity (Poster 6580).
Conducted by the Eastern Oncology...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.